---
title: "AXIM Biotechnologies, Inc. (AXIM.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/AXIM.US.md"
symbol: "AXIM.US"
name: "AXIM Biotechnologies, Inc."
industry: "Biotechnology"
---

# AXIM Biotechnologies, Inc. (AXIM.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.aximbiotech.com](https://www.aximbiotech.com) |

## Company Profile

AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-speci...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-17T04:30:11.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 173 / 404 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 257.95% |  |
| Net Profit YoY | 56.09% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.33M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 92898.00 |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 42.89% | A |
| Profit Margin | -4452.06% | E |
| Gross Margin | 90.02% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 257.95% | A |
| Net Profit YoY | 56.09% | B |
| Total Assets YoY | -12.21% | E |
| Net Assets YoY | 2.21% | C |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -2.25% | D |
| OCF YoY | 257.95% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.02 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 355.78% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - AXIM Biotechnologies, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "42.89%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-4452.06%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "90.02%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "257.95%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "56.09%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.21%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.21%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-2.25%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "257.95%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "355.78%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | Abbvie (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.65 | 158/605 | - | - | - |
| PB | -0.28 | 486/605 | - | - | - |
| PS (TTM) | 29.09 | 225/605 | 29.09 | 24.88 | 17.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/AXIM.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/AXIM.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/AXIM.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.